
MSD has taken a legal hit after a US appeals court upheld a ruling that the pharma giant had illicitly …

Merck KGaA’s Chris Round, Head of EMEA Region, spoke with Pharmafile.com to discuss his time at both the US and …

Pharma heavyweights MSD (Merck) and Eisai have announced they are to join forces to develop and commercialise the latter’s tyrosine …

We’re already into March and, trying to put a bad start to the year behind them on Alzheimer’s research, the …

Just two weeks ago, Merck KGaA and Pfizer were hit with a major setback for their PD-L1 immunotherapy, Bavencio, after …

MSD, known as Merck in the US, has announced it is to buy Australian viral immuno-oncology firm Viralytics for $394 …

Biogen made investors very nervous after it announced that it was choosing to add an additional 510 patients to its …

When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for …

Merck KGaA and Pfizer have been rocked by the news that their jointly-developed anti-PD-L1 antibody failed to meet its primary …

NHS England has entered into a commercial agreement with Merck which aims to provide access to innovative treatments for both …

MSD has revealed its intention to cut 1,800 sales positions from its workforce in the US. Across the total number, …

MSD, known as Merck in North America, has revealed that it will not pursue a regulatory filing for its cholesterol …

Merck KGaA and Pfizer have announced that European authorisation of their jointly developed drug Bavencio (avelumab) as a monotherapy in …

Merck KGaA has revealed plans to continue its commitment to a key partnership with the Ugandan Government via its non-profit …

In a shock move, MSD Chairman and Chief Executive Officer Kenneth Frazier (pictured) has announced that he is to resign …